NRx Pharmaceuticals (NASDAQ:NRXP) Lowered to Strong Sell Rating by Zacks Research

Zacks Research cut shares of NRx Pharmaceuticals (NASDAQ:NRXP) from a hold rating to a strong sell rating in a report issued on Wednesday,Zacks.com reports.

A number of other brokerages have also recently issued reports on NRXP. UBS Group reissued a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday. BTIG Research restated a “buy” rating and set a $10.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, August 18th. Wall Street Zen downgraded NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 5th. Finally, D. Boral Capital reissued a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. Five research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $34.50.

NRx Pharmaceuticals Stock Performance

NRXP opened at $3.62 on Wednesday. NRx Pharmaceuticals has a 52-week low of $1.62 and a 52-week high of $5.05. The business’s fifty day moving average is $3.72 and its 200-day moving average is $3.05. The firm has a market cap of $156.75 million, a P/E ratio of -6.58 and a beta of 2.18.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Monday, August 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The business had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $1.33 million. On average, research analysts predict that NRx Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Anson Funds Management LP lifted its stake in shares of NRx Pharmaceuticals by 50.3% in the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after acquiring an additional 1,018,853 shares during the last quarter. Commonwealth Equity Services LLC acquired a new position in NRx Pharmaceuticals in the 4th quarter worth about $994,000. Bleakley Financial Group LLC bought a new position in NRx Pharmaceuticals in the fourth quarter valued at about $318,000. AdvisorShares Investments LLC raised its position in NRx Pharmaceuticals by 28.2% in the first quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock valued at $896,000 after purchasing an additional 92,463 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of NRx Pharmaceuticals by 18.3% during the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares in the last quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

Key NRx Pharmaceuticals News

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating on NRx Pharmaceuticals, signaling continued confidence in the company’s longer-term prospects despite weaker near-term estimates. HC Wainwright Reiterates Buy Rating for NRx Pharmaceuticals
• Neutral Sentiment: HC Wainwright still forecasts a potential transition to profitability, with estimated EPS of $0.15 in fiscal 2028, $0.71 in 2029 and $1.14 in 2030. However, those projections remain highly dependent on successful execution and future revenue growth.
• Negative Sentiment: The analyst cut projected EPS for the third and fourth quarters of 2026 to losses of $0.43 and $0.50, respectively, from previous estimates of losses of $0.06 and $0.07. Forecasts for the first three quarters of 2027 were also reduced to losses of $0.30, $0.15 and $0.05 per share.
• Negative Sentiment: Full-year earnings estimates were sharply lowered: 2027 moved to a $0.50-per-share loss from a $0.67 profit, while estimates for 2028, 2029 and 2030 fell to $0.15, $0.71 and $1.14 from $2.49, $4.51 and $5.76, respectively. These revisions imply slower commercialization or weaker financial performance than previously expected.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.